2017 Nov 8 - Combined immunohistochemistry and RNA in situ hybridization to elucidate tumor molecular heterogeneity in prostate cancer
Nallasivam Palanisamy, PhD. Vattikuti Urology Institute, Henry Ford Health System
Watch Video:

Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors are highly heterogeneous and there are many studies evaluating the molecular profile or ‘fingerprint’ of prostate cancer.  Conventional analysis reviews the protein expression of key markers via serum analysis and immunohistochemistry (IHC) of the biopsy.  In this presentation we will review how RNA in situ hybridization (ISH) analysis of prostate cancer can unravel the molecular heterogeneity of the tumor, identify molecular subsets and detect key fusions and mutations of the RNA.  We will also present a comparison of IHC and ISH technology and the combination of dual color IHC and dual color ISH can be used to enhance simultaneous evaluation of DNA, RNA and protein, revealing the molecular profile of prostate cancer.

Contact Us

Complete one of the three forms below and we will get back to you.

For Quote Requests, please provide more details in the Contact Sales form below

Advanced Cell Diagnostics

Our new headquarters office starting May 2016:

7707 Gateway Blvd.  
Newark, CA 94560
Toll Free: 1 (877) 576-3636
Phone: (510) 576-8800
Fax: (510) 576-8798



19 Barton Lane  
Abingdon Science Park
OX14 3NB
United Kingdom
Phone 2: +44 1235 529449
Fax: +44 1235 533420


Advanced Cell Diagnostics China

20F, Tower 3,
Raffles City Changning Office,
1193 Changning Road, Shanghai 200051

Web: www.acdbio.com/cn

For general information: Info.ACD@bio-techne.com
For place an order: order.ACD@bio-techne.com
For product support: support.ACD@bio-techne.com
For career opportunities: hr.ACD@bio-techne.com